Table 2. Proportion of ▵MGMT CFU after... | American Society of Hematology

Table 2.

Proportion of ▵MGMT⁺ CFU after drug treatment

No. ΔMGMT⁺ Cells Infused	No. Postinfusion Cycles of BG and BCNU	% ΔMGMT⁺ CFU	BCNU IC90 After 20 μmol/L BG (in μmol/L)
100 × 10⁴	3 (n = 5)	67/69 (97%)	74.5
	2 (n = 4)	54/59 (92%)	45
	1 (n = 4)	13/64 (20%)^*	21
	0 (n = 3)	0/61 (0%)	7
25 × 10⁴	3 (n = 4)	43/50 (86%)	51
	2 (n = 5)	34/69 (49%)	30
	1 (n = 4)	8/56 (14%)^*	15
	0 (n = 3)	0/55 (0%)	6
5 × 10⁴	3 (n = 4)	28/59 (47%)	35
	2 (n = 6)	14/71 (20%)^†	14.5
	1 (n = 4)	3/50 (6%)^‡	13
	0 (n = 3)	0/52 (0%)	6
0 (normal mouse)	0 (n = 9)	N/A	11

No. ΔMGMT⁺ Cells Infused	No. Postinfusion Cycles of BG and BCNU	% ΔMGMT⁺ CFU	BCNU IC90 After 20 μmol/L BG (in μmol/L)
100 × 10⁴	3 (n = 5)	67/69 (97%)	74.5
	2 (n = 4)	54/59 (92%)	45
	1 (n = 4)	13/64 (20%)^*	21
	0 (n = 3)	0/61 (0%)	7
25 × 10⁴	3 (n = 4)	43/50 (86%)	51
	2 (n = 5)	34/69 (49%)	30
	1 (n = 4)	8/56 (14%)^*	15
	0 (n = 3)	0/55 (0%)	6
5 × 10⁴	3 (n = 4)	28/59 (47%)	35
	2 (n = 6)	14/71 (20%)^†	14.5
	1 (n = 4)	3/50 (6%)^‡	13
	0 (n = 3)	0/52 (0%)	6
0 (normal mouse)	0 (n = 9)	N/A	11

In 1 mouse, 0 of 16 CFU tested were ΔMGMT⁺.

In 1 mouse, 0 of 9 CFU tested were ΔMGMT⁺.

In 2 mice, 0 of 15 and 0 of 12 CFU tested were ΔMGMT⁺.